← Back to Screener
Reviva Pharmaceuticals Holdings, Inc. Common Stock (RVPH)
Price$0.61
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-101.57%
Price vs S&P 500 (4W)-16.46%
VGM Score18.08
Market Capitalization$9.16M
All Metrics
Book Value / Share (Quarterly)$1.47
P/TBV (Annual)10.34x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-4.19
Price vs S&P 500 (YTD)-95.34%
EPS (TTM)$-1.92
10-Day Avg Trading Volume0.19M
EPS Excl Extra (TTM)$-1.92
EPS (Annual)$-5.48
ROI (Annual)-219.39%
Cash / Share (Quarterly)$2.46
ROA (Last FY)-124.75%
EBITD / Share (TTM)$-0.74
ROE (5Y Avg)-992.53%
Cash Flow / Share (Annual)$-4.19
P/B Ratio1.06x
P/B Ratio (Quarterly)3.71x
Net Income / Employee (Annual)$-1,418,900
Net Interest Coverage (TTM)-3547.29x
ROA (TTM)-161.01%
EPS Incl Extra (Annual)$-5.48
Current Ratio (Annual)2.08x
Quick Ratio (Quarterly)1.98x
3-Month Avg Trading Volume0.61M
52-Week Price Return-95.53%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-0.38
52-Week High$17.98
EPS Excl Extra (Annual)$-5.48
26-Week Price Return-93.64%
Quick Ratio (Annual)1.98x
13-Week Price Return-83.10%
Total Debt / Equity (Annual)0.05x
Current Ratio (Quarterly)2.08x
Enterprise Value$-4.87M
Book Value / Share Growth (5Y)19.99%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.46
3-Month Return Std Dev222.03%
Net Income / Employee (TTM)$-1,418,500
ROE (Last FY)-229.71%
EPS Basic Excl Extra (Annual)$-5.48
Total Debt / Equity (Quarterly)0.05x
EPS Incl Extra (TTM)$-1.92
ROI (TTM)-108.47%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.60
Price vs S&P 500 (52W)-119.90%
Year-to-Date Return-87.19%
5-Day Price Return19.17%
EPS Normalized (Annual)$-5.48
ROA (5Y Avg)-131.98%
Month-to-Date Return74.73%
EBITD / Share (Annual)$-5.57
LT Debt / Equity (Annual)0.01x
ROI (5Y Avg)-725.25%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.92
P/B Ratio (Annual)3.71x
Book Value / Share (Annual)$1.47
Price vs S&P 500 (13W)-91.35%
Beta0.42x
Revenue / Share (TTM)$0.00
ROE (TTM)-111.82%
52-Week Low$0.26
mGradeF
vgmGradeF
Show chart for
Earnings Surprise History
Q1 26-0.46est. -0.63
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.08
4.08
4.00
4.00
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RVPHReviva Pharmaceuticals Holdings, Inc. Common Stock | — | — | F | $0.61 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Reviva Pharmaceuticals is a late-stage biopharmaceutical company developing therapeutics for central nervous system, inflammatory, and cardiometabolic diseases. Its lead candidate, Brilaroxazine (RP5063), targets multiple neuropsychiatric indications including schizophrenia, bipolar disorder, depression, ADHD, and dementia-related psychosis, with RP1208 also in development. The company uses a chemical genomics-driven platform and proprietary chemistry to discover and develop new medicines.